CSF1R Inhibition with Chemotherapy Relieves Systemic Immune Suppression in Patients with Metastatic Triple-Negative Breast Cancer and Boosts anti-PD-1 Efficacy in Transgenic Mammary Tumors
These clinical and preclinical findings provide rationale for therapies to increase therapeutic index of aPD-1 therapy by diminishing presence of T cell-suppressive myelomonocytic cells to improve outcomes for patients with refractory disease.
Authors
- Amanda Poissonnier (ORCID: https://orcid.org/0000-0002-9027-1159)
- Lisa M. Coussens (ORCID: https://orcid.org/0000-0003-2389-1865)
- Wesley Horton
- Byung Park
- Ingrid A. Mayer (ORCID: https://orcid.org/0000-0001-8147-335X)
- Nell Kirchberger (ORCID: https://orcid.org/0009-0003-7024-705X)
- Shivaani Kummar
- Eivind Valen Egeland (ORCID: https://orcid.org/0000-0002-7273-7277)
- Tiziana Cotechini (ORCID: https://orcid.org/0000-0001-6762-3649)
- Nicky A. Beelen
- Motomi Mori (ORCID: https://orcid.org/0000-0003-1390-4917)
- Amy DeLuca (ORCID: https://orcid.org/0000-0003-2507-6047)
- Kimberly Blackwell
- H. S. Rugo
- Dhaarini Murugan
- Tina Kim
- Yun Yu
- Shamilene Sivagnanam
- E. Shelley Hwang
Institutions
- Oslo University Hospital (NO)
- City Of Hope National Medical Center (US)
- St. Jude Children's Research Hospital (US)
- Oregon Health & Science University (US)
- Duke University (US)
- University of California, San Francisco (US)
- Queen's University (CA)
- Cancer Institute (WIA) (IN)
- Maastricht University (NL)
- AstraZeneca (Netherlands) (NL)
- AstraZeneca (Japan) (JP)
- Tracon Pharmaceuticals (United States) (US)
- Oregon Health and Science University Hospital (US)
- University of San Francisco (US)
Publication Details
- Journal
- Clinical Cancer Research
- Published
- 2026-03-27
- DOI
- https://doi.org/10.1158/1078-0432.ccr-25-4236
- Primary Topic
- Immune cells in cancer
- Type
- article
- Field-Weighted Citation Impact
- 0.00